Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast can...
Mallinckrodt has announced to sell its Canadian drug manufacturing BioVectra Inc. to a Miami-based private equity firm, an affiliate of H.I.G. Capital for approximately USD 250 Million. The agreement included a fixed amount of USD 175 Million, with an upfront amount of USD 135 Million, a long term payment of US...
Find More
Daiichi Sankyo announced the submission of a New Drug Application (NDA) of DS-8201 to Japan's Ministry of Health, Labour and Welfare (MHLW). DS-8201 [fam-] trastuzumab deruxtecan), is an investigational antibody-drug conjugate (ADC) designed to deliver cytotoxic chemotherapy to cancer cells via a human epiderma...
Find More
Breast cancer is not a single disease leading to abnormal cell division in breast tissues. In the United States, it is estimated that more than 40,000 women will die from breast cancer in 2017. According to DelveInsight’s estimates, the total Breast cancer incident population in the 7MM was found to be 626,867 in 2...
Find More
The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies. Opdivo, leading drug of Bristol-Myers Squibb approv...
Find More
Helsinn Group grants exclusive licensing rights to Blanver and Varifarma for its leading drug Pracinostat in South America. Helsinn is a Swiss biopharmaceutical company committed to producing the best solutions aimed at improving the quality of life for people with cancer. Under the terms of the agreements, ...
Find More
FDA urges Pharma giants to increase their inclusion of men in new Breast Cancer trials The recent FDA recommendations have urged the Pharma companies for the inclusion of men in the clinical trials to test new breast cancer drugs. Men rarely develop Breast cancer. Less than 1% of men develop Breast cancer. And 1...
Find More
Every 3 minutes, one person in the United States (U.S.) is diagnosed with blood cancer, as estimated by The Leukemia & Lymphoma Society (LLS). A total number of 176,200 people are expected to be diagnosed with leukaemia, lymphoma or myeloma in 2019. Out of which, 61,780 people are expected to be diagnosed with ...
Find More
The drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The result of the NEPTUNE study was not much of a promising one and has been disclosed completely. The Pharma giant, AstraZeneca, has announced the incompetence of its lead candidate...
Find More
Juvenescence closes a USD 100 Million Series B round Juvenescence, a life sciences company focused on treating ageing problems, has successfully raised USD 100 Million in a Series B round. The investors who took part in the funding were Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian co-...
Find More
Cocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychol.....
Find More
Primary Progressive Aphasia (PPA) is a rare neurological disorder that results from the damages to t.....
Find More.png)
Today, the sedentary lifestyle adopted among people has led to cause a myriad of underlying diseases.....
Find More
HIV-associated lipodystrophy (HAL), is a condition characterized by the redistribution of adipose ti.....
Find More
Delivery of therapeutics to the human eye is among the most interesting endeavours a formulator can .....
Find More
Transthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein i.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
